Рефрактерная множественная миелома: этентамиг снизил риск смерти на 60%
Рефрактерная множественная миелома: этентамиг снизил риск смерти на 60% Medvestnik
145 материалов по теме, собраны автоматически из проверенных источников
Рефрактерная множественная миелома: этентамиг снизил риск смерти на 60% Medvestnik
Today, treatment decisions for patients with mantle cell lymphoma are heavily based on age alone, although the disease can range from slow-growing (indolent) to very aggressive. In a new journal article, Ingrid Glimelius and co-authors suggest that it is time to let the disease's biology also guide treatment—and…
Investigators from the Mass General Brigham Cancer Institute have found that adults with newly diagnosed acute myeloid leukemia (AML) receiving a less-intensive combination of azacitidine and venetoclax had more than twice as much time before treatment failed, the leukemia returned or worsened, or they died, compared…
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia University of Cincinnati